SAN MATEO, Calif., April 7, 2025 /PRNewswire/ — Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round and was recognized on Fast Company’s annual top 10 list of the Most Innovative Medical Device Companies in 2025, announced at the American Academy of Neurology (AAN) meeting in San Diego, CA, the results from multiple clinical studies further expanding the robust body of evidence for Cala TAPS™ Therapy. These studies demonstrate TAPS improves underlying tremor severity with consistent usage, supports TAPS mechanism of action acts on the same brain network as Deep Brain Stimulation (DBS), and shows reduced ET-related healthcare costs over a 12-month prospective study.
Cala Presents Multiple Clinical Studies Demonstrating Impact of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients at the American Academy of Neurology (AAN)
Posted on April 9, 2025
Categories: Coping with ET, ET Treatment
like to know the results.
If you click on the link to download the article online you can see results. They include:
Analysis of data from the multi-center PROSPECT study (263 patients) indicated that consistent usage of Cala TAPS Therapy reduces underlying tremor severity. This effect was measured across eight key daily activities and indicated a substantial underlying improvement in functional capacity, with over 80% of participants demonstrating improvement after one- and three-months of TAPS use at home. These results showed that consistent use of TAPS leads to improvement in underlying tremor severity, expanding the evidence that TAPS offers a valuable therapeutic option for individuals seeking to manage their tremor and regain greater independence in their daily routines.